Human Chorionic Gonadotropin (HCG) Sector: Growth Drivers and Challenges
Growth Drivers
-
Rising Cases of Infertility
-
Increasing in the Incidence of Male Hypogonadism
Challenges
-
Regulations & Warnings Issued by FDA
-
Lack of Accuracy & Specificity
Human Chorionic Gonadotropin (HCG) Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.6% |
|
Base Year Market Size (2024) |
USD 790.19 million |
|
Forecast Year Market Size (2037) |
USD 1.81 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of human chorionic gonadotropin is estimated at USD 834.52 million.
Human Chorionic Gonadotropin (HCG) Market size was valued at USD 790.19 million in 2024 and is likely to cross USD 1.81 billion by 2037, registering more than 6.6% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is poised to hold largest revenue share by 2037, owing to growing population, increasing concern and awareness among the individuals in the region.
The major players in the market are Merck & Co., Cigna, Lee BioSolutions, Swiss Precision Diagnostics GmbH, Abbott Laboratories, Quidel Corporation, Geratherm Medical AG, bioMérieux SA, CIGA Healthcare Ltd, and Others.
